Level Four Advisory Services, LLC Supernus Pharmaceuticals, Inc. Transaction History

Level Four Advisory Services, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jun 05, 2023	BUY	$34.93 - $42.03 $30,982 - $37,280	887 Added 4.41%	21,011 $761,000
Q4 2022 Feb 13, 2023	SELL	$31.09 - $37.88 $230,781 - $281,183	-7,423 Reduced 26.95%	20,124 $717,000
Q3 2022 Nov 07, 2022	BUY	$28.79 - $35.41 $68,203 - $83,886	2,369 Added 9.41%	27,547 $932,000
Q2 2022 Aug 08, 2022	BUY	$25.33 - $34.25 $252,261 - $341,095	9,959 Added 65.44%	25,178 $728,000
Q1 2022 May 10, 2022	BUY	$28.51 - $32.9 $32,444 - $37,440	1,138 Added 8.08%	15,219 $492,000
Q4 2021 Feb 11, 2022	BUY	$26.37 - $34.22 $371,315 - $481,851	14,081 New	14,081 $411,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Level Four Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Level Four Advisory Services, LLC with notifications on news.